Mersana Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MRSN and other ETFs, options, and stocks.

About MRSN

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592.

CEO

Martin H. Huber

CEOMartin H. Huber

Employees

102

Employees102

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2001

Founded2001

Employees

102

Employees102

MRSN Key Statistics

Market cap

39.08M

Market cap39.08M

Price-Earnings ratio

-0.56

Price-Earnings ratio-0.56

Dividend yield

—

Dividend yield—

Average volume

2.28M

Average volume2.28M

High today

$0.3979

High today$0.3979

Low today

$0.3038

Low today$0.3038

Open price

$0.3656

Open price$0.3656

Volume

4.19M

Volume4.19M

52 Week high

$2.83

52 Week high$2.83

52 Week low

$0.2589

52 Week low$0.2589

MRSN News

TipRanks 9h

Positive Developments in Mersana Therapeutics’ TNBC Trials and Stable Financial Position Support Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) today and set a price target of $3.00. Confident I...

TipRanks 15h

Promising Clinical Trial Results and Strategic Development Drive Buy Rating for Mersana Therapeutics

William Blair analyst Andy Hsieh has reiterated their bullish stance on MRSN stock, giving a Buy rating on May 6. Confident Investing Starts Here: Quickly and...

Analyst ratings

89%

of 9 ratings

Buy

88.9%

Hold

11.1%

Sell

People also own

Based on the portfolios of people who own MRSN. This list is generated using Robinhood data, and it’s not a recommendation.